These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31152320)

  • 61. Character-space-limited online prescription drug communications: Four experimental studies.
    Sullivan HW; O'Donoghue A; Mannis S; Carpenter AM
    Res Social Adm Pharm; 2022 Dec; 18(12):4092-4099. PubMed ID: 35961860
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Precious Information: Getting Interpretable, Actionable Health Communications Data.
    Lanthorn H; Moucheraud C; Sheely R
    J Health Commun; 2024 Jun; 29(6):407-408. PubMed ID: 38847276
    [TBL] [Abstract][Full Text] [Related]  

  • 63. What are side effects?
    Due A
    Eur J Philos Sci; 2023; 13(1):16. PubMed ID: 36936702
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antidepressants and suicide in adolescents and adults: a public health experiment with unintended consequences?
    McCain JA
    P T; 2009 Jul; 34(7):355-78. PubMed ID: 20140100
    [No Abstract]   [Full Text] [Related]  

  • 65.
    Cui X; Han B
    Plant Commun; 2020 Jan; 1(1):100018. PubMed ID: 33404543
    [No Abstract]   [Full Text] [Related]  

  • 66. Association Between Data Sources and US Food and Drug Administration Drug Safety Communications.
    Tau N; Shochat T; Gafter-Gvili A; Tibau A; Amir E; Shepshelovich D
    JAMA Intern Med; 2019 Nov; 179(11):1590-1592. PubMed ID: 31479104
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Words Matter: Unintended Side Effects of "Financial Toxicity".
    Blackstone EC; Daly BJ
    J Natl Compr Canc Netw; 2023 Dec; 21(12):1216-1217. PubMed ID: 38081129
    [No Abstract]   [Full Text] [Related]  

  • 68. Unintended Effects of Communicating About Drug Safety Issues: A Critical Review of the Literature.
    DeFrank JT; McCormack L; West SL; Lefebvre C; Burrus O
    Drug Saf; 2019 Oct; 42(10):1125-1134. PubMed ID: 31152320
    [TBL] [Abstract][Full Text] [Related]  

  • 69. FDA drug safety communications: a narrative review and clinical considerations for older adults.
    Marcum ZA; Vande Griend JP; Linnebur SA
    Am J Geriatr Pharmacother; 2012 Aug; 10(4):264-71. PubMed ID: 22683398
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.
    Dusetzina SB; Higashi AS; Dorsey ER; Conti R; Huskamp HA; Zhu S; Garfield CF; Alexander GC
    Med Care; 2012 Jun; 50(6):466-78. PubMed ID: 22266704
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Youth Risk Behavior Surveillance - United States, 2015.
    Kann L; McManus T; Harris WA; Shanklin SL; Flint KH; Hawkins J; Queen B; Lowry R; Olsen EO; Chyen D; Whittle L; Thornton J; Lim C; Yamakawa Y; Brener N; Zaza S
    MMWR Surveill Summ; 2016 Jun; 65(6):1-174. PubMed ID: 27280474
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools.
    Sobel RE; Bate A; Marshall J; Haynes K; Selvam N; Nair V; Daniel G; Brown JS; Reynolds RF
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):332-339. PubMed ID: 29392851
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Consumer Understanding, Preferences, and Responses to Different Versions of Drug Safety Messages in the United States: A Randomized Controlled Trial.
    McCormack L; Craig Lefebvre R; Bann C; Taylor O; Rausch P
    Drug Saf; 2016 Feb; 39(2):171-84. PubMed ID: 26547718
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Methodological approaches to evaluate the impact of FDA drug safety communications.
    Kesselheim AS; Campbell EG; Schneeweiss S; Rausch P; Lappin BM; Zhou EH; Seeger JD; Brownstein JS; Woloshin S; Schwartz LM; Toomey T; Dal Pan GJ; Avorn J
    Drug Saf; 2015 Jun; 38(6):565-75. PubMed ID: 25968811
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.